InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,175.20
(
0.00%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.65
(
0.55%
)
Bitcoin
61,573.18
(
-0.38%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: BTH post# 4689

Friday, 01/07/2011 9:23:13 AM

Friday, January 07, 2011 9:23:13 AM

Post# of 80490
"I guess you better hope that the SUCCEED trial has the majority of its patients NOT in the bone sarcoma category then."

A couple of points you may want to consider. First, the majority of bone sarcomas affect children who, unfortunately, are not eligible for the SUCCEED trial. Second, the most common soft tissue sarcomas are leiomyosarcoma and liposarcoma. To date rida has shown to be particularly efficacious in precisely the sarcomas that are most prevalent.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up